Lapatinib ditosylate, marketed as Tykerb or Tyverb, is a targeted therapy for HER2-positive breast cancer. It is primarily supplied by the original manufacturer, GlaxoSmithKline (GSK), but additional suppliers have entered or are involved in the supply chain.
Leading Suppliers and Manufacturers
Supplier/Manufacturer
Role
Location
Notes
GlaxoSmithKline (GSK)
Original source
United Kingdom
Proprietary rights holder; supplies lapatinib ditosylate globally through licensing and distribution channels.
Fresenius Kabi
Contract manufacturing
Germany
Produces generic formulations for regional markets under licensing agreements.
Sun Pharmaceutical Industries
Contract manufacturing
India
Manufactures generic versions; supplies in Asia, Middle East, and other regions.
Mylan (now part of Viatris)
Generic supplier
United States / Global
Provides generic lapatinib ditosylate, primarily for North American markets.
Dr. Reddy’s Laboratories
Generic supplier
India
Offers generic formulations for emerging markets.
Cipla
Generic supplier
India
Supplies lapatinib ditosylate in select regions.
Licensing and Distribution
GSK retains patent rights until expiration, generally expected around 2028 globally.
Several generic manufacturers operate under licensing agreements or are authorized to produce after patent expiry.
Regional restrictions often limit access; some countries rely solely on GSK's supply, while others access generic versions.
Regulatory Approvals
GSK's lapatinib ditosylate received FDA approval in 2007.
European Medicines Agency (EMA) approval followed in 2008.
Many generic manufacturers obtain approval after patent expiration, which varies by country.
Supply Chain Dynamics
GSK’s manufacturing facilities in the UK and the US produce active pharmaceutical ingredients (API).
Contract manufacturing organizations (CMOs) in India and Germany produce finished formulations.
Market availability depends on regional regulatory approvals, patent status, and licensing agreements.
Regional Market Insights
North America: Dominated by GSK and licensed generics from Mylan and others.
Europe: GSK supplies directly; generics available post-patent expiry.
Asia-Pacific: Multiple generics from Indian manufacturers; regional distribution channels influence availability.
Latin America and Africa: Access constrained by pricing and licensing, with generics gradually increasing market share.
Key Considerations for Procurement
Verify licensing status and patent expiration dates.
Assess quality compliance with international standards (e.g., EMA, FDA).
Evaluate regional distribution policies and regulatory approvals.
Confirm formulation specifications match intended use (e.g., tablet strength, excipients).
Price and Market Trends
Exclusive for GSK until patent expiry; prices are higher under branded supply.
Entry of generics post-patent expiry led to price declines, often by 50% or more.
Regional pricing varies according to regulatory frameworks and procurement policies.
Summary
Lapatinib ditosylate supply chain involves GSK as the primary commercial supplier, with multiple generic companies in India, the US, and Germany classified as significant secondary suppliers. The market landscape will evolve as patent protections expire and generic manufacturing accelerates, affecting global availability and pricing.
Key Takeaways
GSK is the sole supplier of branded lapatinib ditosylate until patent expiry (~2028).
Generics from Indian, US, and European companies are the primary alternative suppliers.
Regulatory approvals and licensing agreements influence regional supply options.
Market prices declined significantly post-generic entry, with regional variations.
Supply chain dynamics depend on manufacturing, licensing, and regulatory status.
Frequently Asked Questions
When does the patent for lapatinib ditosylate expire globally?
Around 2028, but varies by country based on local patent laws.
Which companies produce generic versions of lapatinib ditosylate?
Sun Pharma, Mylan (Viatris), Dr. Reddy’s, Cipla, and others.
How does patent expiry influence market availability?
Patent expiry allows generic manufacturers to produce and sell the drug, increasing competition and reducing prices.
Are generics bioequivalent to the branded drug?
Yes, approved generics must demonstrate bioequivalence to the branded version.
What should buyers consider when sourcing lapatinib ditosylate?
Verify licensing, regulatory approval, formulation specifications, and quality standards.
References
Food and Drug Administration. (2007). Approval of Tykerb (lapatinib).
European Medicines Agency. (2008). Marketing authorization of Tyverb.
GSK. (2022). Lapatinib product information.
Indian Drug Manufacturer’s Association. (2021). Generics and licensing status.
IQVIA. (2022). Global oncology drug market analysis.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
